Yahoo
NYSE - Delayed Quote USD

Biohaven Ltd. (BHVN)

15.42 -1.07 (-6.49%)
At close: 4:00:02 PM EDT
15.41 -0.01 (-0.06%)
After hours: 5:37:23 PM EDT
Trade BHVN on Coinbase
Chart Range Bar
Loading chart for BHVN
  • Previous Close 16.49
  • Open 15.46
  • Bid 14.30 x 20000
  • Ask 15.29 x 30000
  • Day's Range 15.12 - 16.33
  • 52 Week Range 7.48 - 18.24
  • Volume 3,163,867
  • Avg. Volume 3,136,531
  • Market Cap (intraday) 2.329B
  • Beta (5Y Monthly) 3.20
  • PE Ratio (TTM) --
  • EPS (TTM) -4.56
  • Earnings Date Oct 29, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 22.93
  • Zacks Rating Bullish

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

www.biohaven.com

274

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BHVN
36.58%
S&P 500 (^GSPC)
10.73%

1-Year Return

BHVN
11.33%
S&P 500 (^GSPC)
11.11%

3-Year Return

BHVN
44.19%
S&P 500 (^GSPC)
81.91%

5-Year Return

BHVN
162.91%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue --
Earnings -129.28M
Profit Margin 0.00%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

-100M
-50M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

10.00
22.93 Average
15.42 Current
48.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/23/2026
Analyst RBC Capital
Rating Action Maintains
Rating Sector Perform
Price Action Raises
Price Target 19 -> 22

Statistics

View More

Valuation Measures

Annual
As of 10/29/2026
  • Market Cap

    2.49B

  • Enterprise Value

    2.52B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    191.77

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -71.98%

  • Return on Equity (ttm)

    -799.46%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -586.84M

  • Diluted EPS (ttm)

    -4.56

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    267.87M

  • Total Debt/Equity (mrq)

    2,430.33%

  • Levered Free Cash Flow (ttm)

    -256.22M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

15.42 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Daily – Vickers Top Buyers & Sellers for 09/26/2024

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 05/16/2024

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 04/26/2024

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 10/11/2023

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: